Publications by authors named "Ving Lee"

Claim this Profile
E
Exploration of macrocyclic peptide binders to the extracellular CRD domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1).
Jennifer X Qiao, Mark R Witmer, Ving Lee, Tammy C Wang, Patrick C Reid

Bioorg Med Chem Lett· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Selection of Macrocyclic Peptides That Bind STING From an mRNA-Display Library With Split Degenerate Codons.
Chi-Wang Lin, Mary J Harner, Andrew E Douglas, Virginie Lafont, Fei Yu, Ving G Lee

Angew Chem Int Ed Engl· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers.
Michele Modugno, Patrizia Banfi, Fabio Gasparri, Robert Borzilleri, Percy Carter, Ving Lee

Exp Cell Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of a stable isotopically labeled universal surrogate peptide for use as an internal standard in LC-MS/MS bioanalysis of human IgG and Fc-fusion protein drug candidates.
Kimberly Voronin, Alban J Allentoff, Samuel J Bonacorsi, Claudio Mapelli, Sharon X Gong, Ving Lee

J Labelled Comp Radiopharm· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of structure-activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis.
Tasir S Haque, Rogelio L Martinez, Ving G Lee, Douglas G Riexinger, Ming Lei

Peptides· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs.
Tasir S Haque, Ving G Lee, Douglas Riexinger, Ming Lei, Sarah Malmstrom

Peptides· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.
Claudio Mapelli, Sesha I Natarajan, Jean-Philippe Meyer, Margarita M Bastos, Michael S Bernatowicz, Ving G Lee

J Med Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
Ken-Ichi Yoshida, Kiyoshi Nakayama, Masami Ohtsuka, Noriko Kuru, Yoshihiro Yokomizo, Ving J Lee

Bioorg Med Chem· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents.
Ken-ichi Yoshida, Kiyoshi Nakayama, Yoshihiro Yokomizo, Masami Ohtsuka, Makoto Takemura, Ving J Lee

Bioorg Med Chem· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases.
Stephen J Baker, Tsutomu Akama, Yong-Kang Zhang, Vittorio Sauro, Chetan Pandit, Ving Lee

Bioorg Med Chem Lett· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux.
Françoise Van Bambeke, Jean-Marie Pagès, Ving J Lee

Recent Pat Antiinfect Drug Discov· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 5: Carbon-substituted analogues at the C-2 position.
Ken-ichi Yoshida, Kiyoshi Nakayama, Noriko Kuru, Shozo Kobayashi, Masami Ohtsuka, Ving J Lee

Bioorg Med Chem· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme.
Michael G Kornacker, Zhihong Lai, Mark Witmer, Jianghong Ma, Joseph Hendrick, Ving G Lee

Biochemistry· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biowarfare Pathogens. Is the Research Flavor Different Than That of Clinically Relevant Pathogens?
Ving J Lee

Annu Rep Med Chem· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 4: Addressing the problem of poor stability due to photoisomerization of an acrylic acid moiety.
Kiyoshi Nakayama, Noriko Kuru, Masami Ohtsuka, Yoshihiro Yokomizo, Atsunobu Sakamoto, Ving J Lee

Bioorg Med Chem Lett· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 3: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore model.
Kiyoshi Nakayama, Haruko Kawato, Jun Watanabe, Masami Ohtsuka, Ken-ichi Yoshida, Ving J Lee

Bioorg Med Chem Lett· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization.
Kiyoshi Nakayama, Yohei Ishida, Masami Ohtsuka, Haruko Kawato, Ken ichi Yoshida, Ving J Lee

Bioorg Med Chem Lett· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.
Kiyoshi Nakayama, Yohei Ishida, Masami Ohtsuka, Haruko Kawato, Ken-ichi Yoshida, Ving J Lee

Bioorg Med Chem Lett· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic dihydropacidamycin antibiotics: a modified spectrum of activity for the pacidamycin class.
Constantine G Boojamra, Rémy C Lemoine, Johanne Blais, Nicole G Vernier, Karin A Stein, Ving J Lee

Bioorg Med Chem Lett· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
Thomas E Renau, Roger Léger, Lubov Filonova, Eric M Flamme, Michael Wang, Ving J Lee

Bioorg Med Chem Lett· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo antibacterial activity of RWJ-54428, a new cephalosporin with activity against gram-positive bacteria.
David C Griffith, Laurie Harford, Robert Williams, Ving J Lee, Michael N Dudley

Antimicrob Agents Chemother· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
Thomas E Renau, Roger Léger, Rose Yen, Miles W She, Eric M Flamme, Ving J Lee

Bioorg Med Chem Lett· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis